Fate Therapeutics, Inc. (FATE) Institutional Ownership & Insider Trading

155 institutions reported holding Fate Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 6 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FATEFate Therapeutics, Inc.Follow FATE — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 252.8M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

155 institutions held 59.9% of the shares. Across filers that reported both quarters, shares held changed -3.0%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	155	72	-3.0%	55	28	35	27
Mar 26	155	74	+5.5%	54	17	30	13
Dec 25	142	72	+0.9%	28	18	49	15
Sep 25	137	81	+1.0%	38	18	36	16
Jun 25	137	80	-17.5%	41	25	35	18
Mar 25	129	96	-4.3%	38	16	35	36
Dec 24	156	101	-10.3%	41	25	43	37
Sep 24	163	115	-8.4%	38	14	56	27

Fate Therapeutics, Inc. — questions

Who owns Fate Therapeutics, Inc. stock?: 155 institutions reported Fate Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Redmile Group, LLC (10.7%), BlackRock, Inc. (6.1%), VANGUARD PORTFOLIO MANAGEMENT LLC (3.8%).
Are Fate Therapeutics, Inc. insiders buying or selling?: 6 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Fate Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.